SCM
AVDL

Suffolk Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Suffolk Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-129,626
Closed -$2.75M – 139
2015
Q2 		$2.75M Buy
129,626
+4,873
+4% +$87.4K 0.33% 92
2015
Q1 		$2.24M Buy
+124,753
New +$1.95M 0.26% 115

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Suffolk Capital Management's AVDL Position: Q3 2015 in Review

Suffolk Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2015, closing a stake of 129,626 shares — an estimated $2.75M sold.

Suffolk Capital Management first reported a position in AVDL in Q1 2015 and held it in 2 quarters. The position peaked at $2.75M in Q2 2015. 97 funds tracked by Wall St. Rank hold AVDL as of Q3 2015.

  • Suffolk Capital Management reported no remaining Avadel Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Suffolk Capital Management sold 129,626 Avadel Pharmaceuticals shares in Q3 2015, an estimated $2.75M.
  • Suffolk Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Suffolk Capital Management's Avadel Pharmaceuticals position peaked at $2.75M in Q2 2015.
  • 97 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2015.

Based on Suffolk Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.